14-Day FRN - Comment period of changes Sept 2024

Federal Register / Vol. 89, No. 167 / Wednesday, August 28, 2024 / Notices

Proposed FY25 awards (subject to
availability of funding)

Recipient name
California Department of Public Health ...............................................................................................
Chicago Department of Public Health .................................................................................................
Delaware Health and Social Services .................................................................................................
Florida Department of Health ..............................................................................................................
Georgia Department of Public Health .................................................................................................
Houston Health Department ................................................................................................................
Illinois Department of Public Health ....................................................................................................
Indiana State Department of Health ....................................................................................................
Los Angeles County Department of Public Health ..............................................................................
Michigan Department of Health and Human Services ........................................................................
Mississippi State Department of Health ..............................................................................................
New Jersey Department of Health and Senior Services ....................................................................
New York City Department of Health and Mental Hygiene ................................................................
New York State Department of Health ................................................................................................
North Carolina Department of Health and Human Services ...............................................................
Oregon Health Authority ......................................................................................................................
Pennsylvania Department of Health ....................................................................................................
Philadelphia Department of Public Health ...........................................................................................
Puerto Rico Department of Health ......................................................................................................
San Francisco Department of Public Health .......................................................................................
Texas Department of State Health Services .......................................................................................
Virginia Department of Health .............................................................................................................
Washington State Department of Health .............................................................................................

Period of Performance: June 1, 2025,
through May 31, 2030.
Authority: This program is authorized
under Section 318 of the Public Health
Service Act (42 U.S.C. 247c, as
amended).
Dated: August 21, 2024.
Terrance Perry,
Acting Director, Office of Grants Services,
Centers for Disease Control and Prevention.
[FR Doc. 2024–19298 Filed 8–27–24; 8:45 am]
BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Administration for Children and
Families
Proposed Information Collection
Activity; Title IV–E Programs Quarterly
Financial Report (0970–0510)
Children’s Bureau,
Administration on Children, Youth and
Families, Administration for Children
and Families, Department of Health and
Human Services.
ACTION: Request for public comments.
AGENCY:

The Administration for
Children and Families (ACF) Children’s

SUMMARY:

68907

Bureau plans to submit revisions to an
approved generic information collection
(GenIC) under the umbrella generic:
Generic Clearance for Financial Reports
used for ACF Non-Discretionary Grant
Programs (0970–0510). This request
revises form CB–496, the Title IV–E
Programs Quarterly Financial Report,
used by title IV–E agencies to submit
financial claims for the title IV–E
entitlement grant programs.
DATES: Comments due within 14 days of
publication. In compliance with the
requirements of the Paperwork
Reduction Act of 1995, ACF is soliciting
public comment on the specific aspects
of the information collection described
above and below.
ADDRESSES: Copies of the proposed
collection of information can be
obtained and comments may be
forwarded by emailing infocollection@
acf.hhs.gov. All requests should be
identified by the title of the information
collection.
SUPPLEMENTARY INFORMATION:
Description: ACF programs require
detailed financial information from their
grantees that allows ACF to monitor
various specialized cost categories
within each program, to closely manage

$955,472
687,266
390,713
1,034,315
817,044
738,464
516,350
514,626
874,378
688,444
489,198
898,374
1,306,704
594,625
687,023
794,810
524,656
579,853
431,047
643,882
735,652
664,068
738,592

program activities, and to have
sufficient financial information to
enable periodic thorough and detailed
audits. Generic Clearance for Financial
Reports used for ACF Non-Discretionary
Grant Programs allows ACF programs to
efficiently develop and receive approval
for financial reports that are tailored to
specific funding recipients and the
associated needs of the program. For
more information about the umbrella
generic, see: https://www.reginfo.gov/
public/do/PRAViewDocument?ref_
nbr=202108-0970-002
This specific GenIC collects quarterly
cost and caseload data for five title IV–
E programs (i.e., foster care, adoption
assistance, guardianship assistance,
prevention services, and kinship
navigator). The requested changes
include removing reporting items no
longer needed, and the addition or
revision of reporting lines and
instructions required due to recent
changes in program regulations, policy
guidance, and other operational changes
for which further information will
enhance the administration of the
program.
Respondents: Title IV–E agencies

khammond on DSKJM1Z7X2PROD with NOTICES

ANNUAL BURDEN ESTIMATES
Title of information
collection

Number of
respondents

Annual
frequency of
responses

Hourly burden
per response

Annual hourly
burden

Form CB–496 ..................................................................................................

67

4

23

6154

VerDate Sep<11>2014

18:13 Aug 27, 2024

Jkt 262001

PO 00000

Frm 00059

Fmt 4703

Sfmt 4703

E:\FR\FM\28AUN1.SGM

28AUN1

68908

Federal Register / Vol. 89, No. 167 / Wednesday, August 28, 2024 / Notices

Comments: The Department
specifically requests comments on (a)
whether the proposed collection of
information is necessary for the proper
performance of the functions of the
agency, including whether the
information shall have practical utility;
(b) the accuracy of the agency’s estimate
of the burden of the proposed collection
of information; (c) the quality, utility,
and clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Consideration will be given
to comments and suggestions submitted
within 14 days of this publication.
Authority: 42 U.S.C. 671(a)(6), 42
U.S.C. 671(a)(7), 42 U.S.C. 673(a)(8)(B)
and 42 U.S.C. 674(a) and (b)
Mary C. Jones,
ACF/OPRE Certifying Officer.
[FR Doc. 2024–19253 Filed 8–27–24; 8:45 am]
BILLING CODE 4184–73–P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2024–N–0008]

Patient Engagement Advisory
Committee; Notice of Meeting—
Patient-Centered Informed Consent in
Clinical Study
AGENCY:

Food and Drug Administration,

HHS.
ACTION:

Notice.

The Food and Drug
Administration (FDA or Agency)
announces a forthcoming public
advisory committee meeting of the
Patient Engagement Advisory
Committee (the Committee). The general
function of the Committee is to provide
advice and recommendations to the
Agency on FDA’s regulatory issues. The
meeting will be open to the public.
DATES: The meeting will be held on
October 30, 2024, from 10 a.m. to 5 p.m.
Eastern Time.
ADDRESSES: All meeting participants
will be heard, viewed, captioned, and
recorded for this advisory committee
meeting via an online teleconferencing
and/or video conferencing platform.
Answers to commonly asked
questions about FDA advisory
committee meetings may be accessed at:
https://www.fda.gov/Advisory
Committees/AboutAdvisoryCommittees/
ucm408555.htm.

khammond on DSKJM1Z7X2PROD with NOTICES

SUMMARY:

VerDate Sep<11>2014

18:13 Aug 27, 2024

Jkt 262001

FOR FURTHER INFORMATION CONTACT:

Letise Williams, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 5407, Silver Spring,
MD 20993–0002, Letise.Williams@
fda.hhs.gov, 301–796–8398, or FDA
Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area). A notice in the
Federal Register about last-minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly
enough to provide timely notice.
Therefore, you should always check the
Agency’s website at https://
www.fda.gov/AdvisoryCommittees/
default.htm and scroll down to the
appropriate advisory committee meeting
link, or call the advisory committee
information line to learn about possible
modifications before the meeting.
SUPPLEMENTARY INFORMATION:
Agenda: The meeting presentations
will be heard, viewed, captioned, and
recorded through an online
teleconferencing and/or video
conferencing platform. On October 30,
2024, the Committee will discuss and
make recommendations on ‘‘PatientCentered Informed Consent in Clinical
Study of FDA-Regulated Medical
Products.’’ The individuals who
volunteer to participate in clinical
research play an integral role in
advancing scientific knowledge and
supporting the development of
potentially life-saving therapies for
patients in need. Informed consent is a
key element in clinical studies and can
be one of a patient’s first interactions
with the clinical community. Too often,
however, informed consent forms are
lengthy and difficult for potential
research participants to understand.
FDA has worked to improve informed
consent over the years, including
several recent activities such as
developing a draft guidance in
identifying key information in informed
consent.
The Committee will provide
recommendations on the informed
consent process and the areas of focus
of the informed consent. The Committee
will also provide recommendations on
factors to consider when
communicating informed consent to
clinical study participants to increase
the likelihood of participants
understanding the key elements of
research.
FDA intends to make background
material available to the public no later
than 2 business days before the meeting.
If FDA is unable to post the background
material on its website prior to the

PO 00000

Frm 00060

Fmt 4703

Sfmt 4703

meeting, the background material will
be made publicly available on FDA’s
website at the time of the advisory
committee meeting, and the background
material will be posted on FDA’s
website after the meeting. Background
material and the link to the online
teleconference and/or video conference
meeting will be available at https://
www.fda.gov/AdvisoryCommittees/
Calendar/default.htm. Scroll down and
select the appropriate advisory
committee meeting link. The meeting
will include slide presentations with
audio and video components to allow
the presentation of materials in a
manner that most closely resembles an
in-person advisory committee meeting.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the Committee. Written
submissions may be made to the contact
person (see FOR FURTHER INFORMATION
CONTACT) on or before October 3, 2024.
Oral presentations from the public will
be scheduled between approximately 2
p.m. and 3 p.m. Eastern Time. Those
individuals interested in making formal
oral presentations should notify the
contact person (see FOR FURTHER
INFORMATION CONTACT) and submit a
brief statement of the general nature of
the evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation on
or before September 25, 2024. Time
allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can
be reasonably accommodated during the
scheduled open public hearing session,
FDA may conduct a lottery to determine
the speakers for the scheduled open
public hearing session. If the number of
registrants requesting to speak during
the open public hearing is greater than
can be reasonably accommodated
during the scheduled open hearing
portion of the advisory committee
meeting, FDA may conduct a lottery to
determine the speakers who will be
invited to participate. The contact
person will notify interested persons
regarding their request to speak by
September 26, 2024.
Virtual Breakout Session: Individuals
interested in participating in the virtual
breakout scenario discussions will need
to sign up to participate on or before
October 16, 2024. The signup sheet, as
well as additional information
pertaining to the virtual scenario
discussions, will be available at https://
www.fdalive.com/peac. Everyone who
signs up in advance and provides a
valid email address will receive an

E:\FR\FM\28AUN1.SGM

28AUN1